{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:45:58Z","timestamp":1791081958992,"version":"4.1.0"},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1097\/ppo.0b013e31819e30d7","type":"journal-article","created":{"date-parts":[[2010,1,27]],"date-time":"2010-01-27T06:19:34Z","timestamp":1264573174000},"page":"164-168","source":"Crossref","is-referenced-by-count":49,"title":["Late Effects of Hodgkin\u2019s Disease and Its Treatment"],"prefix":"10.1097","volume":"15","author":[{"given":"Andrea K.","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Mauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210203","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/0360-3016(90)90221-5","article-title":"Causes of death after therapy for early stage Hodgkin\u2019s disease entered on EORTC protocols. EORTC Lymphoma Cooperative Group.","volume":"19","author":"Henry-Amar","year":"1990","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"suppl 1","key":"R2-13-20210203","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/annonc\/8.suppl_1.S115","article-title":"Hodgkin\u2019s disease: complications of therapy and excess mortality.","volume":"8","author":"Hoppe","year":"1997","journal-title":"Ann Oncol"},{"key":"R3-13-20210203","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2002.08.021","article-title":"Long-term survival and competing causes of death in patients with early-stage Hodgkin\u2019s disease treated at age 50 or younger.","volume":"20","author":"Ng","year":"2002","journal-title":"J Clin Oncol"},{"key":"R4-13-20210203","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJM197211302872204","article-title":"Nonlymphomatous malignant tumors complicating Hodgkin\u2019s disease. Possible association with intensive therapy.","volume":"287","author":"Arseneau","year":"1972","journal-title":"N Engl J Med"},{"key":"R5-13-20210203","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJM199001043220102","article-title":"Leukemia following Hodgkin\u2019s disease.","volume":"322","author":"Kaldor","year":"1990","journal-title":"N Engl J Med"},{"key":"R6-13-20210203","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1200\/JCO.1994.12.5.1063","article-title":"Leukemia risk following Hodgkin\u2019s disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage.","volume":"12","author":"van Leeuwen","year":"1994","journal-title":"J Clin Oncol"},{"key":"R7-13-20210203","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2004.12.170","article-title":"ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin\u2019s disease: long-term results.","volume":"22","author":"Bonadonna","year":"2004","journal-title":"J Clin Oncol"},{"key":"R8-13-20210203","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/jnci\/djj017","article-title":"Acute myeloid leukemia following Hodgkin lymphoma: a population-based study of 35,511 patients.","volume":"98","author":"Schonfeld","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"R9-13-20210203","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin\u2019s disease.","volume":"348","author":"Diehl","year":"2003","journal-title":"N Engl J Med"},{"key":"R10-13-20210203","first-page":"630","article-title":"Stanford V and radiotherapy for locally extensive and advanced Hodgkin\u2019s disease: mature results of a prospective clinical trial.","volume":"20","author":"Horning","year":"2002","journal-title":"J Clin Oncol"},{"key":"R11-13-20210203","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.2000.18.3.487","article-title":"Long-term risk of second malignancy in survivors of Hodgkin\u2019s disease treated during adolescence or young adulthood.","volume":"18","author":"van Leeuwen","year":"2000","journal-title":"J Clin Oncol"},{"key":"R12-13-20210203","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2000.18.3.498","article-title":"Risk of second malignancy after Hodgkin\u2019s disease in a collaborative British cohort: the relation to age at treatment.","volume":"18","author":"Swerdlow","year":"2000","journal-title":"J Clin Oncol"},{"key":"R13-13-20210203","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1200\/JCO.2001.19.7.2026","article-title":"Non-Hodgkin\u2019s lymphoma after primary Hodgkin\u2019s disease in the German Hodgkin\u2019s Lymphoma Study Group: incidence, treatment, and prognosis.","volume":"19","author":"Rueffer","year":"2001","journal-title":"J Clin Oncol"},{"key":"R14-13-20210203","doi-asserted-by":"crossref","first-page":"7555","DOI":"10.1200\/JCO.2005.08.138","article-title":"Secondary amenorrhea after Hodgkin\u2019s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin\u2019s Lymphoma Study Group.","volume":"23","author":"Behringer","year":"2005","journal-title":"J Clin Oncol"},{"key":"R15-13-20210203","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2006.09.0936","article-title":"Long-term solid cancer risk among 5-year survivors of Hodgkin\u2019s lymphoma.","volume":"25","author":"Hodgson","year":"2007","journal-title":"J Clin Oncol"},{"key":"R16-13-20210203","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jama.290.4.465","article-title":"Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease.","volume":"290","author":"Travis","year":"2003","journal-title":"JAMA"},{"key":"R17-13-20210203","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/jnci\/95.13.971","article-title":"Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin\u2019s disease.","volume":"95","author":"van Leeuwen","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"R18-13-20210203","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/jnci\/94.3.182","article-title":"Lung cancer following chemotherapy and radiotherapy for Hodgkin\u2019s disease.","volume":"94","author":"Travis","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"R19-13-20210203","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1200\/JCO.2001.19.6.1610","article-title":"Lung cancer after Hodgkin\u2019s disease: a nested case-control study of the relation to treatment.","volume":"19","author":"Swerdlow","year":"2001","journal-title":"J Clin Oncol"},{"key":"R20-13-20210203","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1001\/jama.1993.03510160067031","article-title":"Factors affecting late mortality from heart disease after treatment of Hodgkin\u2019s disease.","volume":"270","author":"Hancock","year":"1993","journal-title":"JAMA"},{"key":"R21-13-20210203","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0167-8140(00)00166-3","article-title":"Long-term cardiac mortality following radiation therapy for Hodgkin\u2019s disease: analysis with the relative seriality model.","volume":"55","author":"Eriksson","year":"2000","journal-title":"Radiother Oncol"},{"key":"R22-13-20210203","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0360-3016(00)00647-7","article-title":"The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin\u2019s disease: University of Minnesota experience.","volume":"48","author":"Lee","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R23-13-20210203","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0735-1097(03)00759-9","article-title":"Asymptomatic cardiac disease following mediastinal irradiation.","volume":"42","author":"Heidenreich","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R24-13-20210203","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1200\/JCO.2004.09.109","article-title":"Cardiovascular status in long-term survivors of Hodgkin\u2019s disease treated with chest radiotherapy.","volume":"22","author":"Adams","year":"2004","journal-title":"J Clin Oncol"},{"key":"R25-13-20210203","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.ahj.2004.12.026","article-title":"Diastolic dysfunction after mediastinal irradiation.","volume":"150","author":"Heidenreich","year":"2005","journal-title":"Am Heart J"},{"key":"R26-13-20210203","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/10428190500063229","article-title":"Late cardiac toxicity secondary to treatment in Hodgkin\u2019s disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy.","volume":"46","author":"Aviles","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"R27-13-20210203","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1001\/jama.290.21.2831","article-title":"Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy.","volume":"290","author":"Hull","year":"2003","journal-title":"JAMA"},{"key":"R28-13-20210203","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/cncr.2820690528","article-title":"Coronary artery disease mortality in patients treated for Hodgkin\u2019s disease.","volume":"69","author":"Boivin","year":"1992","journal-title":"Cancer"},{"key":"R29-13-20210203","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1200\/JCO.1993.11.7.1208","article-title":"Cardiac disease following treatment of Hodgkin\u2019s disease in children and adolescents.","volume":"11","author":"Hancock","year":"1993","journal-title":"J Clin Oncol"},{"key":"R30-13-20210203","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0167-8140(97)00125-4","article-title":"Cardiac risk after mediastinal irradiation for Hodgkin\u2019s disease.","volume":"46","author":"Glanzmann","year":"1998","journal-title":"Radiother Oncol"},{"key":"R31-13-20210203","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma.","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"key":"R32-13-20210203","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","article-title":"Long-term cause-specific mortality of patients treated for Hodgkin\u2019s disease.","volume":"21","author":"Aleman","year":"2003","journal-title":"J Clin Oncol"},{"key":"R33-13-20210203","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/jnci\/djk029","article-title":"Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study.","volume":"99","author":"Swerdlow","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"R34-13-20210203","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1200\/JCO.2006.07.0805","article-title":"Screening for coronary artery disease after mediastinal irradiation for Hodgkin\u2019s disease.","volume":"25","author":"Heidenreich","year":"2007","journal-title":"J Clin Oncol"},{"key":"R35-13-20210203","doi-asserted-by":"crossref","first-page":"6508","DOI":"10.1200\/JCO.2005.15.107","article-title":"Stroke as a late treatment effect of Hodgkin\u2019s Disease: a report from the Childhood Cancer Survivor Study.","volume":"23","author":"Bowers","year":"2005","journal-title":"J Clin Oncol"},{"key":"R36-13-20210203","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJM199108293250902","article-title":"Thyroid diseases after treatment of Hodgkin\u2019s disease.","volume":"325","author":"Hancock","year":"1991","journal-title":"N Engl J Med"},{"key":"R37-13-20210203","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1097-0142(19840215)53:4<878::AID-CNCR2820530411>3.0.CO;2-J","article-title":"Thyroid dysfunction after radiotherapy in children with Hodgkin\u2019s disease.","volume":"53","author":"Constine","year":"1984","journal-title":"Cancer"},{"key":"R38-13-20210203","first-page":"3227","article-title":"Abnormalities of the thyroid in survivors of Hodgkin\u2019s disease: data from the Childhood Cancer Survivor Study.","volume":"85","author":"Sklar","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R39-13-20210203","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1634\/theoncologist.1-1-62","article-title":"Thyroid Abnormalities after Therapy for Hodgkin\u2019s Disease in Childhood.","volume":"1","author":"Bhatia","year":"1996","journal-title":"Oncologist"},{"key":"R40-13-20210203","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/j.1939-4640.1983.tb00765.x","article-title":"The effect of testicular x-irradiation on spermatogenesis in man. A comparison with the mouse.","volume":"4","author":"Clifton","year":"1983","journal-title":"J Androl"},{"key":"R41-13-20210203","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/1097-0142(197602)37:2+<1111::AID-CNCR2820370821>3.0.CO;2-E","article-title":"The effects of gonadal irradiation in clinical radiation therapy: a review.","volume":"37","author":"Lushbaugh","year":"1976","journal-title":"Cancer"},{"key":"R42-13-20210203","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000474582","article-title":"Effects of chemotherapy and radiotherapy on spermatogenesis.","volume":"23","author":"Meistrich","year":"1993","journal-title":"Eur Urol"},{"issue":"suppl 2","key":"R43-13-20210203","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1289\/ehp.93101s2109","article-title":"Effect of radiation on the human reproductive system.","volume":"101","author":"Ogilvy-Stuart","year":"1993","journal-title":"Environ Health Perspect"},{"key":"R44-13-20210203","first-page":"155","article-title":"Risk of infertility in patients with Hodgkin\u2019s disease treated with ABVD vs MOPP vs ABVD\/MOPP.","volume":"75","author":"Anselmo","year":"1990","journal-title":"Haematologica"},{"key":"R45-13-20210203","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.2006.10.2020","article-title":"Gonadal function in males after chemotherapy for early-stage Hodgkin\u2019s lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte.","volume":"25","author":"van der Kaaij","year":"2007","journal-title":"J Clin Oncol"},{"key":"R46-13-20210203","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/0277-5379(85)90088-4","article-title":"Gonadal toxicity after combination chemotherapy for Hodgkin\u2019s disease. Comparative results of MOPP vs ABVD.","volume":"21","author":"Viviani","year":"1985","journal-title":"Eur J Cancer Clin Oncol"},{"key":"R47-13-20210203","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2007-02-073544","article-title":"Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG).","volume":"111","author":"Sieniawski","year":"2008","journal-title":"Blood"},{"key":"R48-13-20210203","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1002\/(SICI)1097-0142(19991115)86:10<2138::AID-CNCR36>3.0.CO;2-V","article-title":"Laparoscopic oophoropexy and ovarian function in the treatment of Hodgkin disease.","volume":"86","author":"Williams","year":"1999","journal-title":"Cancer"},{"key":"R49-13-20210203","first-page":"541","article-title":"Laparoscopic oophoropexy for preservation of ovarian function before pelvic node irradiation.","volume":"80","author":"Williams","year":"1992","journal-title":"Obstet Gynecol"},{"key":"R50-13-20210203","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood-2007-05-090225","article-title":"Treatment-related risk factors for premature menopause following Hodgkin lymphoma.","volume":"111","author":"De Bruin","year":"2008","journal-title":"Blood"},{"key":"R51-13-20210203","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/hon.802","article-title":"Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy.","volume":"25","author":"Hodgson","year":"2007","journal-title":"Hematol Oncol"},{"key":"R52-13-20210203","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijrobp.2006.03.063","article-title":"Clinical dose-volume histogram analysis in predicting radiation pneumonitis in Hodgkin\u2019s lymphoma.","volume":"66","author":"Koh","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R53-13-20210203","doi-asserted-by":"crossref","first-page":"6505a","DOI":"10.1200\/jco.2005.23.16_suppl.6505","article-title":"First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin\u2019s lymphoma (HL).","volume":"23","author":"Noordijk","year":"2005","journal-title":"J Clin Oncol"},{"key":"R54-13-20210203","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2006.05.015","article-title":"Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines.","volume":"79","author":"Girinsky","year":"2006","journal-title":"Radiother Oncol"},{"key":"R55-13-20210203","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.canrad.2005.09.020","article-title":"Radiation treatment in non Hodgkin\u2019s lymphomas: present and future directions.","volume":"9","author":"Girinsky","year":"2005","journal-title":"Cancer Radiother"},{"key":"R56-13-20210203","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.radonc.2007.10.016","article-title":"Heart and coronary artery protection in patients with mediastinal Hodgkin lymphoma treated with intensity-modulated radiotherapy: dose constraints to virtual volumes or to organs at risk?","volume":"87","author":"Ghalibafian","year":"2008","journal-title":"Radiother Oncol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0b013e31819e30d7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:25:57Z","timestamp":1620969957000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130404-200904000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0b013e31819e30d7","relation":{},"ISSN":["1528-9117"],"issn-type":[{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}